Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRK

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 14 strange trades.

Benzinga

5 Resilient Stocks to Own During a Market Downturn

The stock market closed the last trading session of May in the red, underscoring inflation fears and rising oil prices. Furthermore, strategists expect the broad market to decline further, given the inflationary pressures and the Fed’s monetary tightening. Hence, we think stocks that have outpaced the broader market so far…

StockNews.com

3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

CHMP Supports Approval Of Merck's Keytruda As Adjuvant In Post Surgery Melanoma Setting

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending Merck & Co Inc (NYSE:MRK) Keytruda in melanoma setting. The opinion covers Keytruda as a monotherapy adjuvant treatment for adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have…

Benzinga

Merck & Co Whale Trades For May 18

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Stocks to Buy After Handily Beating Earnings Estimates

Given current market volatility due to concerns over the Fed's tighter monetary policy to tame surging inflation and fears of an economic slowdown, we think investors should consider buying stocks with sound fundamentals and solid growth attributes. Nutrien (NTR), Merck & Co (MRK), and Bunge (BG) recently reported promising quarterly…

StockNews.com

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

5 Strong Stocks Bucking the Market Downtrend

The S&P 500 experienced its worst period since 1939 between January and April this year. The stock market has been under pressure due to investor fears about looming interest rate increases, geopolitical tensions, and rising inflation. Hence, we think it might be best now to bet on fundamentally sound stocks…

StockNews.com

What 7 Analyst Ratings Have To Say About Merck & Co

Over the past 3 months, 7 analysts have published their opinion on Merck & Co (NYSE:MRK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

Benzinga

Merck & Co Whale Trades For April 19

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

Where Merck & Co Stands With Analysts

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:

Benzinga

Merck Expands Elkton Manufacturing Facility To Boost HPV Vaccine Supply

Merck & Co Inc (NYSE: MRK) has invested in manufacturing and recently expanded its vaccines manufacturing facility in Elkton, VA.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Merck - Ridgeback's COVID-19 Antiviral Shows Rapid Elimination Of Infectious SARS-CoV-2 Than Placebo

Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics will present data evaluating Lagevrio (molnupiravir), an oral COVID-19 antiviral, at the 2022 European Congress of Clinical Microbiology & Infectious Diseases.

Benzinga

FDA Pushes Merck's Pneumococcal Vaccine Decision Date Into July For Expanded Use In Kids

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental marketing application for Merck & Co Inc's (NYSE: MRK) pneumococcal 15-valent conjugate vaccine

StockNews.com

3 Healthcare Stocks to Buy for the Long Run

The healthcare industry has achieved significant growth over the past two years in-part because the COVID-19 pandemic fostered a stream of hefty private and federal investments in the sector. With accelerating advancement and increased tech integration in healthcare, we expect renowned companies Pfizer Inc. (PFE), Merck & Co., Inc. (MRK),…

StockNews.com

4 Surging Dow Jones Stocks to Add to Your Watchlist

Despite volatile market conditions currently, owing in varying degrees to the Russia-Ukraine crisis and a hawkish Fed, a continuing economic rebound is still expected by many experts. With the slight easing of investor concerns, the Dow Jones Industrial Average has witnessed a solid recovery since mid-March. So, we think it…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga

EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Merck & Co Inc (NYSE: MRK) for

Benzinga

Merck Continues to See Executive Exodus; Here's A Look At All Recent Departures

Executive churn at pharma giant Merck & Co., Inc. (NYSE: MRK) has increased in recent times, so much so that it has caused stakeholders to sit up and take notice.

Benzinga

Merck Lays Out Keytruda Data In Post Surgery Early-Stage Lung Cancer Setting

Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 KEYNOTE-091 trial evaluating Keytruda compared to placebo for adjuvant treatment of non-small cell lung cancer (NSCLC).

Benzinga

Analyzing Merck & Company Inc. New's Short Interest

Merck & Company Inc (new's (NYSE: MRK) short percent of float has fallen 12.5% since its last report. The company recently reported that it has 17.65 million shares sold short, which is 0.7% of all regular shares that are available for trading.

Benzinga

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

Why Alpine Immune's Shares Are Falling Today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and…

1 … 6 7 8 9

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.